NO972451L - Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav - Google Patents

Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav

Info

Publication number
NO972451L
NO972451L NO972451A NO972451A NO972451L NO 972451 L NO972451 L NO 972451L NO 972451 A NO972451 A NO 972451A NO 972451 A NO972451 A NO 972451A NO 972451 L NO972451 L NO 972451L
Authority
NO
Norway
Prior art keywords
thiadiazolidin
heterocyclyloxy
thiomethyl
dioxides
preparations
Prior art date
Application number
NO972451A
Other languages
English (en)
Other versions
NO972451D0 (no
Inventor
John J Court
Ranjit C Desai
Dennis John Hlasta
Original Assignee
Sanofi Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Winthrop Inc filed Critical Sanofi Winthrop Inc
Publication of NO972451D0 publication Critical patent/NO972451D0/no
Publication of NO972451L publication Critical patent/NO972451L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cosmetics (AREA)

Abstract

Det blir beskrevet 2-heterocyklyloksy- og tiometyl-l,2,5-tiadiazolidin-3-on-l,l-diok-syder, farmasøytiske sammensetninger inneholdende disse og fremgangsmåter for behandlingen av degenerative sykdommer ved bruk av disse.
NO972451A 1994-12-02 1997-05-29 Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav NO972451L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/348,421 US5494925A (en) 1994-12-02 1994-12-02 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
PCT/US1995/015563 WO1996016649A1 (en) 1994-12-02 1995-11-30 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof

Publications (2)

Publication Number Publication Date
NO972451D0 NO972451D0 (no) 1997-05-29
NO972451L true NO972451L (no) 1997-07-25

Family

ID=23367973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972451A NO972451L (no) 1994-12-02 1997-05-29 Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav

Country Status (12)

Country Link
US (1) US5494925A (no)
EP (1) EP0793494A4 (no)
JP (1) JPH10510535A (no)
CN (1) CN1173130A (no)
AU (1) AU703719B2 (no)
CA (1) CA2205970A1 (no)
FI (1) FI972309A7 (no)
HU (1) HUT77086A (no)
MX (1) MX9704030A (no)
NO (1) NO972451L (no)
NZ (1) NZ297342A (no)
WO (1) WO1996016649A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6420401B1 (en) 1997-08-22 2002-07-16 Wichita State University 1,2,5, thiadiazolidin-3-one 1,1-dioxide derivatives
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
PE20040570A1 (es) * 2002-10-09 2004-08-30 Pharmacopeia Drug Discovery Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina
US7432292B2 (en) * 2002-12-30 2008-10-07 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20080045531A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
EP1694659B8 (en) * 2003-12-19 2008-10-08 Schering Corporation Thiadiazoles as cxc- and cc- chemokine receptor ligands
CA2550540A1 (en) * 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
WO2007005403A1 (en) * 2005-06-29 2007-01-11 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
MX2008000366A (es) * 2005-06-29 2008-03-07 Schering Corp Oxadiazoles di-sustituidos como ligandos del receptor cxc-quimiocina.
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CA2684950A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6228013B2 (ja) * 2013-02-13 2017-11-08 Ｊｘｔｇエネルギー株式会社 潤滑油基油の製造方法
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637614B2 (en) * 1989-05-04 1993-06-03 Sanofi Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4141218A1 (de) * 1991-12-13 1993-06-17 Luitpold Werk Chem Pharm Thiadiazincarbonsaeureamidderivate, verfahren zu ihrer herstellung und arzneimittel
US5378720A (en) * 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors

Also Published As

Publication number Publication date
CA2205970A1 (en) 1996-06-06
WO1996016649A1 (en) 1996-06-06
US5494925A (en) 1996-02-27
MX9704030A (es) 1998-02-28
NZ297342A (en) 1999-05-28
CN1173130A (zh) 1998-02-11
HUT77086A (hu) 1998-03-02
JPH10510535A (ja) 1998-10-13
FI972309L (fi) 1997-07-30
EP0793494A1 (en) 1997-09-10
AU4248396A (en) 1996-06-19
NO972451D0 (no) 1997-05-29
FI972309A7 (fi) 1997-07-30
EP0793494A4 (en) 1998-01-28
FI972309A0 (fi) 1997-05-30
AU703719B2 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
NO20002835L (no) 2-aryl-oksodihydropurinderivater, fremgangsmÕte for fremstilling av disse medisinske preparater inneholdende disse, og mellomprodukter derfor
NO20002788D0 (no) Nye forbindelser
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
NO932620L (no) Amindiol-proteaseinhibitorer
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
NO975987D0 (no) 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater
DK0386452T3 (da) Diphenylheteroalkylderivater, fremgangsmåde til fremstilling heraf og lægemidler og kosmetika indeholdende disse
IL94278A0 (en) 2-saccharine derivatives,their preparation and pharmaceutical compositions containing them
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
NO880179D0 (no) Polymerkomplekser, fremgangsmaate for fremstilling av disse, og farmasoeytiske midler inneholdende disse.
GR3020355T3 (en) Aminosulfonyl urea acat inhibitors
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
NO930796D0 (no) Glykopeptidderivater, fremgangsmaate for deres fremstilling og farmasoeytiske midler inneholdende disse
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
DK1100775T3 (da) 2,5-Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til fremstilling deraf, anvendelse deraf og farmaceutiske præparater indeholdende disse
NO962243D0 (no) Halogenarylsubstituerte metallkomplekser, farmasöytiske midler inneholdende slike og deres anvendelse i diagnostikken, samt fremgangsmåte for fremstilling av slike komplekser og midler
IL115826A (en) Pharmaceutical composition comprising erythropoietin for the treatment of rheumatoid arthritis